相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Junji Tsurutani et al.
Cancer Discovery (2020)
Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer Long-term Results of Treatment With Trastuzumab and Lapatinib
Andrea Sartore-Bianchi et al.
JAMA ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
Federica Tosi et al.
CLINICAL COLORECTAL CANCER (2020)
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colrectal cancer: the phase II HERACLES-B trial
Andrea Sartore-Bianchi et al.
ESMO OPEN (2020)
Comprehensive review of targeted therapy for colorectal cancer
Yuan-Hong Xie et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification
Naoki Takegawa et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
ONCOLOGIST (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara et al.
LANCET ONCOLOGY (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura et al.
LANCET ONCOLOGY (2019)
526PDTRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study
Y Nakamura et al.
ANNALS OF ONCOLOGY (2019)
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
S. Siena et al.
ANNALS OF ONCOLOGY (2018)
Targeting HER2 in Colorectal Cancer: The Landscape of Amplification and Short Variant Mutations in ERBB2 and ERBB3
Jeffrey S. Ross et al.
CANCER (2018)
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
Giulia Siravegna et al.
CANCER CELL (2018)
Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
Kentaro Sawada et al.
CLINICAL COLORECTAL CANCER (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies
A. Vogel et al.
CANCER TREATMENT REVIEWS (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers
Andreas H. Marx et al.
HUMAN PATHOLOGY (2010)
分享论文
